title: Long term pharmacotherapy by methylfenidate or atomoxetine DAT 1 10/10 ADHD children in correlation with results of the imaging methods.
abstract: OBJECTIVE
  ADHD is one of the most significant diagnostic units in child and adolescent psychiatry. The occurrence in children is 5-6% and 50-80% continued to adult age. The presence of individual genes (polymorphism) on particular symptoms and processes in ADHD are not known. It is estimated that ADHD symptoms are up to 80% to genetic. The higher density of resultant DAT 1 protein was observed in ADHD patients in comparison with controls. The question was if DAT 1 10/10 predicted bad prognoses in long term therapy.
  
  
  METHODS
  We compared 30 ADHD DAT 1 10/10 adolescents treated for 5-6 years. Patients with 30 control adolescents. They were the same age of probands and controls. All these subjects were examined by child psychiatry scales (Conners, Achenbach…). Biological changes were tested by MRI specific CNS volumometry.
  
  
  RESULTS
  We didn't confirm bad prognoses in long term therapy with methylphenidate or atomoxetine in ADHD children DAT 1 10/10 in long term therapy. In MRI specific CNS volumometry were not identify any differences in controls and ADHD probands. Gray matter thickness was significantly higher in prefrontal and occipital areas in patients compared to control in prefrontal and occipital areas with cluster-wise p-value<0.05. By this method were not identify any cerebrum damage in long term therapy by methylphenidate and atomoxetine.
authors.affiliation: Department of Psychiatry, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
authors.forename: Nikol
authors.initials: N
authors.lastname: Pribilova
authors.affiliation: Department of Psychiatry, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
authors.forename: Ivo
authors.initials: I
authors.lastname: Paclt
authors.affiliation: Department of Psychiatry, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
authors.forename: Patricie
authors.initials: P
authors.lastname: Kollarova
authors.affiliation: Department of Biology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
authors.forename: Milada
authors.initials: M
authors.lastname: Kohoutova
authors.affiliation: Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, MR Unit, Prague, Czech Republic.
authors.forename: Monika
authors.initials: M
authors.lastname: Dezortova
authors.affiliation: Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, MR Unit, Prague, Czech Republic.
authors.forename: Milan
authors.initials: M
authors.lastname: Hajek
authors.affiliation: Prague Psychiatric Centre, Prague, Czech Republic.
authors.forename: Ladislav
authors.initials: L
authors.lastname: Csemy
mesh_terms: D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D000069445:Atomoxetine Hydrochloride / Q000627:therapeutic use*; D001289:Attention Deficit Disorder with Hyperactivity / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000235:genetics; D001921:Brain / Q000000981:diagnostic imaging* / Q000473:pathology; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D050483:Dopamine Plasma Membrane Transport Proteins / Q000235:genetics*; D005260:Female; D066128:Gray Matter / Q000000981:diagnostic imaging / Q000473:pathology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008774:Methylphenidate / Q000627:therapeutic use*; D009778:Occipital Lobe / Q000000981:diagnostic imaging / Q000473:pathology; D009929:Organ Size; D011110:Polymorphism, Genetic; D017397:Prefrontal Cortex / Q000000981:diagnostic imaging / Q000473:pathology; D011379:Prognosis
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000697:Central Nervous System Stimulants; D050483:Dopamine Plasma Membrane Transport Proteins; C493214:SLC6A3 protein, human; D008774:Methylphenidate; D000069445:Atomoxetine Hydrochloride